Bergers and Hanahan concluded in 2008 that anti-VEGF drugs can show therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
Bergers e Hanahan concluíron en 2008 que os fármacos anti-VEGF poden mostrar eficacia terapéutica en modelos de ratos do cancro e nun crecente número de cancros humanos.